BR0108219A - Uso oftálmico de agentes bloqueadores alfa-adrenérgicos - Google Patents

Uso oftálmico de agentes bloqueadores alfa-adrenérgicos

Info

Publication number
BR0108219A
BR0108219A BR0108219-1A BR0108219A BR0108219A BR 0108219 A BR0108219 A BR 0108219A BR 0108219 A BR0108219 A BR 0108219A BR 0108219 A BR0108219 A BR 0108219A
Authority
BR
Brazil
Prior art keywords
alpha
blocking agents
adrenergic blocking
ophthalmic solution
therapeutically effective
Prior art date
Application number
BR0108219-1A
Other languages
English (en)
Inventor
Miles A Galin
Original Assignee
Miles A Galin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles A Galin filed Critical Miles A Galin
Publication of BR0108219A publication Critical patent/BR0108219A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"USO OFTáLMICO DE AGENTES BLOQUEADORES ALFA-ADRENéRGICOS". São descritos métodos e composições para inibição de anomalias visuais indesejáveis comumente experimentadas por indivíduos que foram submetidos à cirurgia refrativa ocular, incluindo fotofobia, ofuscamento, imagens secundárias, e formação de halos no campo visual. Em particular, a presente invenção propicia a aplicação tópica ocular de uma solução oftálmica ao olho, em que a solução oftálmica contém uma quantidade terapeuticamente eficaz de um ou mais agentes bloqueadores alfa adrenérgicos, preferivelmente timoxamina. Adicionalmente, a invenção propicia uma solução oftálmica contendo um ou mais agentes bloqueadores alfa adrenérgicos em um veículo fisiologicamente aceitável, que pode será administrado em um indivíduo em uma dose eficaz para ser terapeuticamente eficaz em relação à concentração e à taxa de liberação. é também descrita uma solução oftálmica para inibição de uma ou mais anomalias visuais indesejáveis experimentadas por um indivíduo que foi submetido à cirurgia refrativa ocular e contendo uma quantidade terapeuticamente eficaz de um ou mais agentes bloqueadores alfa adrenérgicos em combinação com um ou mais agentes antiirritantes e/ou um ou mais agentes antiinflamatórios.
BR0108219-1A 2000-02-10 2001-02-09 Uso oftálmico de agentes bloqueadores alfa-adrenérgicos BR0108219A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/501,400 US6730691B1 (en) 2000-02-10 2000-02-10 Uses of alpha adrenergic blocking agents
PCT/US2001/004316 WO2001058438A1 (en) 2000-02-10 2001-02-09 Ophthalmic use of alpha adrenergic blocking agents

Publications (1)

Publication Number Publication Date
BR0108219A true BR0108219A (pt) 2004-04-27

Family

ID=23993399

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0108219-1A BR0108219A (pt) 2000-02-10 2001-02-09 Uso oftálmico de agentes bloqueadores alfa-adrenérgicos

Country Status (10)

Country Link
US (1) US6730691B1 (pt)
EP (1) EP1255540A1 (pt)
JP (1) JP2003535817A (pt)
KR (1) KR20030061301A (pt)
AU (1) AU2001236868A1 (pt)
BR (1) BR0108219A (pt)
CA (1) CA2398158A1 (pt)
IL (1) IL151171A0 (pt)
MX (1) MXPA02007698A (pt)
WO (1) WO2001058438A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082288A1 (en) * 1999-09-16 2002-06-27 Gerald Horn Ophthalmic formulations comprising an imidazoline
US6730065B1 (en) * 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US20060211753A1 (en) * 2000-11-03 2006-09-21 Ocularis Pharma, Inc. Method and composition which reduces stimulation of muscles which dilate the eye
FR2874811B1 (fr) * 2004-09-03 2006-11-24 Anteis Sa Dispositif oculaire antiphotophobie, et son procede de preparation
JP5098156B2 (ja) * 2005-11-16 2012-12-12 大正製薬株式会社 水分分泌促進剤
US20070154523A1 (en) * 2005-12-30 2007-07-05 Rick Lewis Controlled pupil dilation for diagnostic and treatment of visual anomalies
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
CN104093404B (zh) 2011-09-20 2016-12-07 阿勒根公司 用于治疗老花眼、轻度远视和不规则散光的组合物和方法
CA2899339C (en) 2013-02-01 2021-07-06 Ocularis Pharma, Llc Aqueous ophthalmic solutions of phentolamine and medical uses thereof
US9089560B2 (en) 2013-02-01 2015-07-28 Ocularis Pharma, Llc Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
US20200121652A1 (en) * 2017-06-16 2020-04-23 The Doshisha Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent
KR102619458B1 (ko) 2017-06-16 2023-12-29 학교법인 도시샤 mTOR 인히비터를 포함하는, 눈의 증상, 장해 또는 질환을 치료 또는 예방하기 위한 의약 및 그 응용
JP2022505950A (ja) 2018-10-26 2022-01-14 オキュフィア・ファーマ・インコーポレイテッド 老眼、散瞳、および他の眼障害の治療のための方法および組成物
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3658963A (en) 1970-07-07 1972-04-25 Warner Lambert Co Method of reducing intraocular pressure with a basic thymol ether
US3966779A (en) 1973-04-30 1976-06-29 Warner-Lambert Company Thymol derivatives and a process for their preparation
IT1094076B (it) 1978-04-18 1985-07-26 Acraf Cicloalchiltriazoli
IT1209160B (it) 1979-12-20 1989-07-10 Blasinachim Spa Processo per la sintesi di 4-[2-(dimetilammino)-etossi]2-metil-5-81-metiletil)-fenol-este ri
US4310524A (en) 1980-04-11 1982-01-12 Richardson-Merrell, Inc. TCA Composition and method for rapid onset antidepressant therapy
US5514672A (en) 1981-02-17 1996-05-07 Bazzano; Gail S. Use of retinoids and compositions containing same for hair growth
EP0062596B1 (fr) 1981-04-06 1985-07-03 Cortial S.A. Nouveaux dérivés d'aminoéthoxy-4 isopropyl-5 méthyl-2 phénol, leur méthode de préparation et leur emploi en tant que médicaments
US4443441A (en) 1981-08-07 1984-04-17 Galin Miles A Fixation of intraocular lenses
US4490379A (en) 1984-04-04 1984-12-25 Steven Podos Method of reducing intraocular pressure and treating glaucoma using corynanthine
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US4795758A (en) 1986-02-10 1989-01-03 Societe A Responsabilite Limitee: Institut De Recherches Chimiques Et Biologiques Appliquees (I.R.C.E.B.A.) 5-[2-(pyrrolidin-1-yl)ethoxy]-p-cymene derivatives, the process for the preparation of the said derivatives and drugs in which the said derivatives are present
US4879304A (en) 1987-05-01 1989-11-07 Angelini Pharmaceuticals Ltd. Ophthalmic compositions and process for preparing
US4879294A (en) 1988-01-28 1989-11-07 Angelini Pharmaceuticals Ltd. Opthalmic composition
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5446070A (en) 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
CA1334168C (en) 1988-04-26 1995-01-31 Louis M. De Santis Antiglaucoma compositions containing combinations of .alpha.-2 agonists and .beta. blockers
IT1224250B (it) 1988-06-10 1990-09-26 Acraf Associzione del depiprazolo con la morfina
US5116615A (en) 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
US5182270A (en) 1989-08-03 1993-01-26 Iolab Corporation Stabilizing preparation for thymoxamine
US5660851A (en) 1989-12-26 1997-08-26 Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem Ocular inserts
US5334138A (en) 1990-03-15 1994-08-02 North Carolina State University Method and composition for increased skin concentration of active agents by iontophoresis
IT1252603B (it) 1990-04-19 1995-06-19 Giorgio Cavallini 2,4-diamino-6 piperidino pirimidina-3 ossido topico sul glande nel trattamento delle impotenze erettili
IT1250701B (it) 1991-07-24 1995-04-21 Angelini Francesco Ist Ricerca Composizione farmaceutica solida per uso orale a base di dapiprazolo
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
EP0648118A1 (en) 1992-07-02 1995-04-19 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5288759A (en) 1992-08-27 1994-02-22 Alcon Laboratories, Inc. Use of certain sulfamoyl-substituted phenethylamine derivatives to reverse drug-induced mydriasis
US5811547A (en) 1992-10-14 1998-09-22 Nippon Shinyaju Co., Ltd. Method for inducing crystalline state transition in medicinal substance
IT1264020B (it) 1993-01-28 1996-09-09 Recordati Chem Pharm Procedimento per la preparazione di microgranuli idonei alla sospensione in liquidi
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
FR2703908B1 (fr) 1993-04-13 1995-06-02 Asta Medica Ag Forme pharmaceutique pour administration rectale de composés pharmacologiquement actifs.
US5571177A (en) 1993-06-14 1996-11-05 Allergan IOL structured for post-operative re-positioning and method for post-operative IOL re-positioning
US5853751A (en) 1993-06-23 1998-12-29 Masiz; John J. Molecular transdermal transport system
US5565466A (en) 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
US5545626A (en) 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
JP2706755B2 (ja) 1994-02-10 1998-01-28 日本たばこ産業株式会社 新規なベンジルアミノエトキシベンゼン誘導体
US5512577A (en) 1994-06-02 1996-04-30 Creighton University Bicyclic hexahydroaporphine and 1-benzyloctahydroisoquinoline therapeutic compositions and processes for utilizing said compositions
IL114193A (en) * 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
US5561154A (en) 1994-07-27 1996-10-01 Institut De Recherches Chimiques Et Bioloques Appliquees Irceba Treatment of acute urinary retention
US5451609A (en) 1994-07-27 1995-09-19 Institut De Recherches Chimiques Et Al Treatment of impotence
FR2726770B1 (fr) 1994-11-16 1997-01-31 Lhd Lab Hygiene Dietetique Dispositif d'administration transdermique de medicaments pour le traitement de l'impuissance erectile masculine
US5972326A (en) 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US5612027A (en) 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US5620416A (en) 1995-06-07 1997-04-15 North Carolina State University Methods of using topical agents with systemically administered active agents
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6540990B2 (en) 2000-09-22 2003-04-01 Gerard M. Nolan Physiological method of improving vision
US6273092B1 (en) 2000-09-22 2001-08-14 Gerard M. Nolan Methods for treating various eye disorders

Also Published As

Publication number Publication date
JP2003535817A (ja) 2003-12-02
AU2001236868A1 (en) 2001-08-20
CA2398158A1 (en) 2001-08-16
MXPA02007698A (es) 2004-09-10
WO2001058438A1 (en) 2001-08-16
KR20030061301A (ko) 2003-07-18
US6730691B1 (en) 2004-05-04
EP1255540A1 (en) 2002-11-13
IL151171A0 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
BR0108219A (pt) Uso oftálmico de agentes bloqueadores alfa-adrenérgicos
BR0312095A (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
ATE184598T1 (de) Enniatine und enniatinderivate zur bekämpfung von endoparasiten
ES2061252T3 (es) Agente antitusivo y regulador de la mucosa, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
BRPI0407485A (pt) utilização de anticorpos anti-receptores de factor crescimento i semelhantes aos anti-insulina
BR9908030A (pt) Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado
BRPI0408784A (pt) método para usar um composto
AR024227A1 (es) Pirimidinas inhibidoras de replicacion de hiv, un proceso para su preparacion, el uso de las mismas para la manufactura de un medicamento, composiciones farmaceuticas, y un proceso para prepararlas
BR0214988A (pt) S-enanciÈmero de um composto, composto, formulação farmacêutica, método de tratamento ou prevenção de distúrbios de lipìdeo, uso de um composto, método de tratamento ou prevenção de diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica
TR199901411T2 (xx) Analjezik etkili yeni bile�imler.
EA200700232A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
BR9509807A (pt) Composição líquida para administração oral e processo para tratar um mamífero incluindo o homem que esteja sofrendo de um quadro clinico mediado pela aç o do 5ht nos receptores 5ht3
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
BR9914901A (pt) Agonistas do receptor 5ht1 e metoclopramida para o tratamento de enxaqueca
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
Mottini et al. The role of postoperative antibiotics in facial fractures: comparing the efficacy of a 1-day versus a prolonged regimen
PA8485601A1 (es) Azalidas de 13 miembros y su uso como agentes antibioticos.
BRPI0017528B1 (pt) Use of a composition containing cetoothene salt
BR9507677A (pt) Composto composição farmacéutica processo para a profilaxia ou para o tratamento de condições associadas à inflamação à artrite ou à dor em um mamifero uso do composto processo para a preparação do composto e novo intermediário
ATE311928T1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
BR0015172A (pt) Nova combinação compreendendo um agonista adreno receptor de beta 2 (beta 2) e um antagonista receptor de leucotrieno
JP2001322936A (ja) 眼科用組成物
CA2137961A1 (en) Cyclic depsipeptides having 18 ring atoms, and their use for combating endoparasites
DK0593520T3 (da) Forbindelser med indhold af steroider og deres anvendelse til behandling af glaucom

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6O, 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2016 DE 25/08/2009